乳腺癌相关心脏毒性研究现状的回顾与评述  

A review of current research on breast cancer-related cardiotoxicity

作　　者：吕丹 王延风 马飞 Lv Dan;Wang Yanfeng;Ma Fei(Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Comprehensive Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院内科,北京100021 [2]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院综合科,北京100021

出　　处：《实用肿瘤杂志》2022年第3期232-236,共5页Journal of Practical Oncology

基　　金：中国医学科学院医学与健康科技创新工程(2021-I2M-1-014)。

摘　　要：近些年,随着乳腺癌患者的5年生存率不断提高,抗肿瘤治疗相关的心血管疾病已成为乳腺癌患者最常见的非肿瘤死亡因素。早期识别抗肿瘤治疗相关的心脏毒性对提高患者生存质量和改善预后有重要意义。本文就乳腺癌治疗相关的心血管不良事件研究现状作一简要回顾和评述,旨在加强肿瘤科医师和心血管科医师的共同关注与协同合作,让更多的肿瘤患者获益。In recent years,with the continuous improvement of the 5-year survival rate of breast cancer patients,cardiovascular diseases related to antitumor therapy have become the most common cause of death in breast cancer patients.Early identification of cardiotoxicity associated with antitumor therapy is of great significance to improve the quality of life and prognosis of patients.The article briefly reviews the current research progression on cardiovascular adverse events related to breast cancer in order to strengthen the attention and coopera-tion between oncologists and cardiologists,so as to benefit more breast cancer patients.

关 键 词：乳腺癌 肿瘤心脏病学 心脏毒性 抗肿瘤治疗 

分 类 号：R737.9[医药卫生—肿瘤]